Short-Acting Insulin Market Report 2026

Short-Acting Insulin Market Overview

• Short-Acting Insulin market size has reached to $11.54 billion in 2025 • Expected to grow to $14.87 billion in 2030 at a compound annual growth rate (CAGR) of 5.2% • Growth Driver: Surging Type 1 Diabetes Prevalence Highlights Need For Effective Insulin Therapy • Market Trend: Advancing Interchangeable Rapid-Acting Insulin For Flexible Diabetes Management • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Short-Acting Insulin Market?

Short-acting insulin is a type of insulin that is used to control blood sugar levels during or after meals. It begins to work within 30 minutes to 1 hour, peaks at around 2-3 hours, and has a duration of action of 4-6 hours. Short-acting insulin plays a vital role in regulating blood glucose by facilitating the uptake of glucose into cells, which the body then uses for energy, particularly after the consumption of food. The main formulation types of short-acting insulin are regular insulin and rapid-acting insulin. Regular insulin is a fast-acting form of insulin used to control blood sugar levels in people with diabetes, typically administered before meals. These formulations are available in different dosage forms, including vials, pre-filled pens, and cartridges, and are administered through subcutaneous or intravenous routes. It is prescribed for both type 1 and type 2 diabetes patients and distributed through various channels, such as retail pharmacies, hospital pharmacies, and online pharmacies.

What Is The Short-Acting Insulin Market Growth Forecast?

The short-acting insulin market size is expected to see strong growth in the next few years. It will grow to $14.87 billion in 2030 at a compound annual growth rate (CAGR) of 5.2%. The growth in the forecast period can be attributed to rising type 2 diabetes incidence, increasing insulin dependence, growth in home-based diabetes care, expansion of insulin delivery technologies, rising demand for fast-acting insulin. Major trends in the forecast period include rising demand for post-meal blood glucose control, increasing use of rapid-acting insulin analogues, growing adoption of pre-filled insulin pens, expansion of intensive insulin therapy regimens, increased focus on tight glycemic management.

Global Short-Acting Insulin Market Segmentation

1) By Formulation: Regular Insulin, Rapid-Acting Insulin 2) By Dosage Form: Vials, Pre-filled Pens, Cartridges 3) By Route Of Administration: Subcutaneous, Intravenous 4) By Patient Type: Type 1 Diabetes, Type 2 Diabetes 5) By Distribution Channel: Pharmacies, Hospital Pharmacies, Online Pharmacies Subsegments: 1) By Regular Insulin: Human Regular Insulin, Animal-Derived Regular Insulin, Other Regular Insulin 2) By Rapid-Acting Insulin: Insulin Lispro, Insulin Aspart, Insulin Glulisine

What Is The Driver Of The Short-Acting Insulin Market?

The increasing prevalence of type 1 diabetes is expected to fuel the growth of the short-acting insulin market going forward. Type 1 diabetes is an autoimmune condition where the body destroys insulin-producing cells, requiring lifelong insulin therapy. The rising prevalence of Type 1 diabetes is driven by genetic factors, environmental triggers, and increasing autoimmune disorders. Short-acting insulin helps manage type 1 diabetes by providing rapid blood sugar control and mimicking natural insulin response. For instance, in December 2023, according to Diabetes Australia, an Australia-based organization that works to raise awareness about diabetes, in 2022, approximately 134,000 Australians were living with Type 1 diabetes. This figure increased to 135,423 in 2023. Therefore, the increasing prevalence of type 1 diabetes is driving the growth of the short-acting insulin industry.

Key Players In The Global Short-Acting Insulin Market

Major companies operating in the short-acting insulin market are Sanofi S.A., Eli Lilly and Company, Novo Nordisk A/S, Biocon Limited, Lupin Limited, Wockhardt Ltd., Julphar (Gulf Pharmaceutical Industries), Geropharm LLC, Bioton S.A., Gan & Lee Pharmaceuticals Co. Ltd., Lannett Company Inc., MannKind Corporation, ADOCIA S.A.S., Baxter International Inc., Tonghua Dongbao Pharmaceutical Co. Ltd., United Laboratories International Holdings Ltd., Bharat Biotech International Ltd., Shanghai Fosun Pharmaceutical Group Co. Ltd., Dongbao Enterprise Group Co. Ltd., Aspen Pharmacare Holdings Limited

Global Short-Acting Insulin Market Trends and Insights

Major companies operating in the short-acting insulin market are focusing on innovative products such as interchangeable rapid-acting insulin biologic to enhance glycemic control and provide flexible substitution options for patients with diabetes. Interchangeable rapid-acting insulin biologic refers to a biologically derived insulin formulation that acts quickly to lower blood glucose levels after meals and is approved by regulatory authorities to be substituted for another equivalent insulin product without requiring a new prescription, offering flexibility in diabetes management and maintaining consistent glycemic control. For instance, in July 2025, Biocon Biologics, a US-based biosimilars company headquartered in India and the U.S., secured FDA approval for Kirsty (insulin aspart xjhz) the first and only interchangeable rapid-acting insulin aspart in the United States. Kirsty is a biosimilar to NovoLog (insulin aspart), with clinical and analytical data demonstrating no meaningful differences in safety, efficacy, purity, and potency. It is available as a 100 units/mL formulation in both a single-patient-use prefilled pen (for subcutaneous use) and a multi-dose vial (for both subcutaneous and intravenous administration), aimed at improving glycemic control in adults and children with diabetes mellitus.

What Are Latest Mergers And Acquisitions In The Short-Acting Insulin Market?

In December 2024, Lupin Limited, an India-based pharmaceutical company, acquired the Humulin range in India from Eli Lilly & Company for an undisclosed amount. With this acquisition, Lupin aims to strengthen its position in the insulin market in India by expanding its product portfolio with the addition of Huminsulin from Eli Lilly and Company. Eli Lilly and Company is a US-based pharmaceutical company specializing in insulin products such as short-acting insulin.

Regional Insights

North America was the largest region in the short-acting insulin market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Short-Acting Insulin Market?

The short-acting insulin market consists of sales of human insulin, analogue insulin, and biosimilars. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Short-Acting Insulin Market Report 2026?

The short-acting insulin market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the short-acting insulin industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.